Lv51
940 积分 2022-11-11 加入
RNA Therapeutics
2天前
已完结
RNA chemistry and therapeutics
2天前
已完结
Effects of MASH risk genotypes on resmetirom efficacy in patients with MASH and fibrosis
4天前
待确认
Heart–liver co-management in MASLD: expert perspectives and recommendations from a multidisciplinary cardiometabolic framework
27天前
已完结
Heart–liver co-management in MASLD: expert perspectives and recommendations from a multidisciplinary cardiometabolic framework
1个月前
已完结
Molecular mechanisms and pathogenesis of MASH
1个月前
已完结
An Industry Perspective on Key Considerations for the ICH S13 Guidance: Nonclinical Safety Evaluations of Oligonucleotide-Based Therapeutics
1个月前
已完结
Clinical and Immunologic Features of a Patient With Homozygous FNIP1 Variant
1个月前
已完结
Folliculin-interacting protein 1: From molecular structure to disease and therapeutic targets
1个月前
已完结
Recompensation in decompensated cirrhosis
2个月前
已完结
皖公网安备34019202002308
